サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1785749

アトピー性皮膚炎の臨床試験の世界市場

Atopic Dermatitis Clinical Trials

出版日
ページ情報
英文 216 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.66円
アトピー性皮膚炎の臨床試験の世界市場
出版日: 2025年08月07日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 216 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

アトピー性皮膚炎の臨床試験の世界市場は2030年までに50億米ドルに到達

2024年に28億米ドルと推定されるアトピー性皮膚炎の臨床試験の世界市場は、2024年から2030年にかけてCAGR 10.4%で成長し、2030年には50億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである低分子は、CAGR12.3%を記録し、分析期間終了時には30億米ドルに達すると予想されます。大型分子セグメントの成長率は、分析期間中CAGR 8.0%と推定されます。

米国市場は7億2,750万米ドルと推定、中国はCAGR 9.4％で成長すると予測

米国のアトピー性皮膚炎の臨床試験市場は、2024年には7億2,750万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに7億6,980万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは9.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ9.5%と8.3%と予測されています。欧州では、ドイツがCAGR 8.0%で成長すると予測されています。

世界のアトピー性皮膚炎の臨床試験市場- 主要動向と促進要因のまとめ

アトピー性皮膚炎治療の臨床試験はどのように進んでいるか？

慢性炎症性皮膚疾患であるアトピー性皮膚炎は、効果的な治療法の特定を目的とした臨床試験の大幅な進展を促しています。これらの臨床試験は、アンメット・メディカル・ニーズに対応するため、生物学的製剤、JAK阻害剤、非ステロイド系外用剤などの新規治療に焦点を当てています。個別化医療（personalized medicine）のアプローチが注目されるようになり、病状に影響を与える遺伝的、環境的要因を調査しています。ウェアラブルデバイスや遠隔医療など、実世界のエビデンスとデジタルヘルスツールの統合は、臨床試験の効率と患者の関与を高めています。これらの技術革新は、アトピー性皮膚炎に対する標的療法の開発を加速させています。

どのような動向がアトピー性皮膚炎の臨床試験を牽引しているのか？

いくつかの動向がアトピー性皮膚炎の臨床試験の状況を形成しています。特に小児におけるアトピー性皮膚炎の有病率の高まりが、調査に拍車をかけています。製薬会社はこの競合領域で市場シェアを獲得するため、生物学的製剤や低分子薬剤に多額の投資を行っています。利便性と遠隔モニタリングに重点を置いた患者中心の試験デザインは、採用率と維持率を向上させています。さらに、革新的治療に対するファスト・トラック指定などの規制上のインセンティブにより、試験スケジュールが迅速化されています。これらの動向は、アトピー性皮膚炎に対する効果的で利用しやすい治療法の開発が急務であることを反映しています。

なぜ生物製剤がアトピー性皮膚炎研究を支配しているのか？

生物学的製剤は、アトピー性皮膚炎に関与する特定の免疫経路を標的とすることができるため、アトピー性皮膚炎研究の焦点として浮上してきました。デュピルマブのようなモノクローナル抗体は、患者の症状を軽減し、QOLを改善する顕著な効果を示しています。既存の生物学的製剤の成功は、IL-13やIL-31のような新たな標的のさらなる探求を促し、この分野の技術革新を牽引しています。これらの治療薬は、特に中等症から重症のアトピー性皮膚炎患者にとって、長期的な疾患管理に希望を与えるものであり、臨床試験での注目度を高めています。

アトピー性皮膚炎の臨床試験市場の成長を促すものは何か？

アトピー性皮膚炎の臨床試験市場の成長の原動力は、疾患有病率の上昇、生物学的製剤の進歩、患者中心のアプローチの採用増加です。標的治療への需要が、製薬会社の革新的な治療パイプラインへの投資を促しています。希少疾病用医薬品の指定や迅速な承認などの規制上の支援は、臨床試験活動のインセンティブとなっています。さらに、デジタルヘルス技術の統合は、臨床試験業務を合理化し、患者の転帰を改善しています。これらの要因が、アトピー性皮膚炎の臨床試験市場の大きな成長の可能性を裏付けています。

セグメント

分子タイプ（低分子、高分子）、試験デザイン（介入試験、観察試験）、フェーズ（第I相臨床試験、第II相臨床試験、第III相臨床試験、第IV相臨床試験）

調査対象企業の例

  • Amgen Inc.
  • Biocytogen
  • Charles River Laboratories International, Inc.
  • Eli Lilly and Company
  • Hooke Laboratories, LLC
  • Imavita S.A.S.
  • Novartis International AG
  • Novotech
  • Oncodesign Services
  • Pfizer, Inc.
  • QIMA Life Sciences
  • Redoxis
  • Regeneron Pharmaceuticals, Inc.
  • ReproCELL, Inc.
  • Syneos Health

AI統合

Global Industry Analystsは、有効な専門家コンテンツとAIツールで市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中のドメイン専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP29298

Global Atopic Dermatitis Clinical Trials Market to Reach US$5.0 Billion by 2030

The global market for Atopic Dermatitis Clinical Trials estimated at US$2.8 Billion in the year 2024, is expected to reach US$5.0 Billion by 2030, growing at a CAGR of 10.4% over the analysis period 2024-2030. Small Molecules, one of the segments analyzed in the report, is expected to record a 12.3% CAGR and reach US$3.0 Billion by the end of the analysis period. Growth in the Large Molecules segment is estimated at 8.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$727.5 Million While China is Forecast to Grow at 9.4% CAGR

The Atopic Dermatitis Clinical Trials market in the U.S. is estimated at US$727.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$769.8 Million by the year 2030 trailing a CAGR of 9.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.5% and 8.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.0% CAGR.

Global Atopic Dermatitis Clinical Trials Market - Key Trends & Drivers Summarized

How Are Clinical Trials Advancing Atopic Dermatitis Treatments?

Atopic dermatitis, a chronic inflammatory skin condition, has prompted significant advancements in clinical trials aimed at identifying effective treatments. These trials focus on novel therapies, including biologics, JAK inhibitors, and non-steroidal topical formulations, to address unmet medical needs. Personalized medicine approaches are gaining prominence, with researchers exploring genetic and environmental factors influencing the condition. The integration of real-world evidence and digital health tools, such as wearable devices and telemedicine, is enhancing trial efficiency and patient engagement. These innovations are accelerating the development of targeted therapies for atopic dermatitis.

What Trends Are Driving Atopic Dermatitis Clinical Trials?

Several trends are shaping the atopic dermatitis clinical trials landscape. The rising prevalence of the condition, particularly in pediatric populations, has spurred research initiatives. Pharmaceutical companies are investing heavily in biologics and small-molecule drugs to capture market share in this competitive space. Patient-centric trial designs, emphasizing convenience and remote monitoring, are improving recruitment and retention rates. Additionally, regulatory incentives, such as fast-track designations for innovative treatments, are expediting trial timelines. These trends reflect the urgency to develop effective and accessible therapies for atopic dermatitis.

Why Are Biologics Dominating Atopic Dermatitis Research?

Biologics have emerged as a focal point in atopic dermatitis research due to their ability to target specific immune pathways implicated in the condition. Monoclonal antibodies, such as dupilumab, have demonstrated significant efficacy in reducing symptoms and improving quality of life for patients. The success of existing biologics has encouraged further exploration of new targets, such as IL-13 and IL-31, driving innovation in the field. These therapies offer hope for long-term disease management, especially for patients with moderate to severe forms of atopic dermatitis, reinforcing their prominence in clinical trials.

What Drives the Growth in the Atopic Dermatitis Clinical Trials Market?

The growth in the atopic dermatitis clinical trials market is driven by rising disease prevalence, advancements in biologics, and increasing adoption of patient-centric approaches. The demand for targeted therapies has encouraged pharmaceutical companies to invest in innovative treatment pipelines. Regulatory support, including orphan drug designations and expedited approvals, has incentivized clinical trial activities. Additionally, the integration of digital health technologies is streamlining trial operations and improving patient outcomes. These factors collectively underscore the significant growth potential of the atopic dermatitis clinical trials market.

SCOPE OF STUDY:

The report analyzes the Atopic Dermatitis Clinical Trials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Molecule Type (Small Molecules, Large Molecules); Study Design (Interventional Trials, Observational Trials); Phase (Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial, Phase IV Clinical Trial)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

  • Amgen Inc.
  • Biocytogen
  • Charles River Laboratories International, Inc.
  • Eli Lilly and Company
  • Hooke Laboratories, LLC
  • Imavita S.A.S.
  • Novartis International AG
  • Novotech
  • Oncodesign Services
  • Pfizer, Inc.
  • QIMA Life Sciences
  • Redoxis
  • Regeneron Pharmaceuticals, Inc.
  • ReproCELL, Inc.
  • Syneos Health

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Atopic Dermatitis Clinical Trials - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Surge in Biologic Therapies Spurs Advanced Clinical Trials
    • Growing Focus on Personalized Medicine Enhances Trial Design Complexity
    • Increasing Prevalence of Atopic Dermatitis Boosts Research Investments
    • Advancements in Genetic and Biomarker Research Drive Trial Innovation
    • Rising Pediatric Cases Lead to Specialized Trial Segments
    • Demand for Faster FDA Approvals Accelerates Adaptive Trial Designs
    • Patient-Centric Approaches Improve Trial Recruitment and Retention
    • Use of Digital Health Tools Enhances Remote Monitoring in Trials
    • Real-World Evidence Integration Expands Post-Trial Market Insights
    • Emergence of Novel Topical Therapies Broadens Clinical Pipelines
    • Artificial Intelligence Streamlines Trial Matching and Site Selection
    • Global Expansion of Trials Increases Access to Diverse Patient Populations
    • Strategic Partnerships Between Pharma and CROs Improve Trial Execution
    • Government and NGO Funding Accelerates Early-Stage Research
    • Emphasis on Long-Term Safety Data Drives Extended Trial Durations
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Atopic Dermatitis Clinical Trials Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Atopic Dermatitis Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Atopic Dermatitis Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Small Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Large Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Large Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Large Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Interventional Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Interventional Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Interventional Trials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Observational Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Observational Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Observational Trials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Phase I Clinical Trial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Phase I Clinical Trial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Phase I Clinical Trial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Phase II Clinical Trial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Phase II Clinical Trial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Phase II Clinical Trial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Phase III Clinical Trial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Phase III Clinical Trial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Phase III Clinical Trial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Phase IV Clinical Trial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Phase IV Clinical Trial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Phase IV Clinical Trial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Atopic Dermatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Atopic Dermatitis Clinical Trials by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Atopic Dermatitis Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Trials and Observational Trials for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Atopic Dermatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Atopic Dermatitis Clinical Trials by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Atopic Dermatitis Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Trials and Observational Trials for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Atopic Dermatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial for the Years 2015, 2025 & 2030
  • JAPAN
    • Atopic Dermatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Atopic Dermatitis Clinical Trials by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Atopic Dermatitis Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Trials and Observational Trials for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Atopic Dermatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial for the Years 2015, 2025 & 2030
  • CHINA
    • Atopic Dermatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Atopic Dermatitis Clinical Trials by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Atopic Dermatitis Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Trials and Observational Trials for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Atopic Dermatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial for the Years 2015, 2025 & 2030
  • EUROPE
    • Atopic Dermatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Atopic Dermatitis Clinical Trials by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Atopic Dermatitis Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Atopic Dermatitis Clinical Trials by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Atopic Dermatitis Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Trials and Observational Trials for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Atopic Dermatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial for the Years 2015, 2025 & 2030
  • FRANCE
    • Atopic Dermatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Atopic Dermatitis Clinical Trials by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Atopic Dermatitis Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Trials and Observational Trials for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Atopic Dermatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial for the Years 2015, 2025 & 2030
  • GERMANY
    • Atopic Dermatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Atopic Dermatitis Clinical Trials by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Atopic Dermatitis Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Trials and Observational Trials for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Atopic Dermatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Atopic Dermatitis Clinical Trials by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Atopic Dermatitis Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Trials and Observational Trials for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Atopic Dermatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Atopic Dermatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Atopic Dermatitis Clinical Trials by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Atopic Dermatitis Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Trials and Observational Trials for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Atopic Dermatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Rest of Europe Historic Review for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Rest of Europe 15-Year Perspective for Atopic Dermatitis Clinical Trials by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Rest of Europe 15-Year Perspective for Atopic Dermatitis Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Trials and Observational Trials for the Years 2015, 2025 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Rest of Europe 15-Year Perspective for Atopic Dermatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Atopic Dermatitis Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific Historic Review for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Asia-Pacific 15-Year Perspective for Atopic Dermatitis Clinical Trials by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Asia-Pacific 15-Year Perspective for Atopic Dermatitis Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Trials and Observational Trials for the Years 2015, 2025 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Asia-Pacific 15-Year Perspective for Atopic Dermatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 131: Rest of World Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of World Historic Review for Atopic Dermatitis Clinical Trials by Molecule Type - Small Molecules and Large Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of World 15-Year Perspective for Atopic Dermatitis Clinical Trials by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Atopic Dermatitis Clinical Trials by Study Design - Interventional Trials and Observational Trials Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of World 15-Year Perspective for Atopic Dermatitis Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Trials and Observational Trials for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Atopic Dermatitis Clinical Trials by Phase - Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of World 15-Year Perspective for Atopic Dermatitis Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial and Phase IV Clinical Trial for the Years 2015, 2025 & 2030

IV. COMPETITION